New therapeutic approaches in Alzheimer's disease.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that affects a large proportion of the elderly population. It causes a progressive decline in memory and other cognitive functions. There is no effective treatment of AD despite the great effort in trying to find one. Herein new therapeutic approaches including those closely targeting the pathogenesis of the disease have been discussed. Potential disease modifying treatments that are being considered as future treatment of AD include avaccination, secretase inhibitors, cholesterol lowering drugs, metal chelators and anti- inflammatory agents. According to Evidence Based Dementia Practice, only inhibitors of acetylcholinesterase (AChE) are approved in mild and moderate stages of AD treatment. From the end of 2003, FDA also approved memantine for much severer phases of AD. When all the presented possibilities are taken into account, the most important target for scientists and physicians is not only to find ways for causative cure of AD, but also to be ready for that moment. There is a great need for finding routine biomarkers and sensitive enough clinical tests for diagnosis of AD in which the lasting pathological process does not destroy too many neurones.

[1]  David H. Cribbs,et al.  Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome , 2004, Neuron.

[2]  C. Masters,et al.  Copper, β-amyloid, and Alzheimer's disease: Tapping a sensitive connection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[3]  C. Finch,et al.  Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[4]  C. Holmes,et al.  Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.

[5]  D. Schenk.  Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning , 2002, Nature Reviews Neuroscience.

[6]  T. Golde,et al.  Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease. , 2001, Drug discovery today.

[7]  H. Feldman,et al.  A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease , 2001, Neurology.

[8]  C. Soto,et al.  Protein misfolding and disease; protein refolding and therapy , 2001, FEBS letters.

[9]  C. Masters,et al.  Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice , 2001, Neuron.

[10]  E. Kojro,et al.  Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  F. D. Miller,et al.  Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brain , 2000, Journal of neurochemistry.

[12]  J. C. Torre.  Critically attained threshold of cerebral hypoperfusion: can it cause Alzheimer's disease? , 2000 .

[13]  G. Wilcock,et al.  The cholinergic hypothesis of Alzheimer’s disease: a review of progress , 1999, Journal of neurology, neurosurgery, and psychiatry.

[14]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[15]  William J. Ray,et al.  A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain , 1999, Nature.

[16]  P Dal-Bianco,et al.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. , 1999, BMJ.

[17]  B. Strooper,et al.  Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Coyle,et al.  Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. , 1982, Science.

[19]  M. Riepe,et al.  Memantine in Moderate-to-severe Alzheimer's Disease , 2006 .

[20]  C. Masters,et al.  Copper, beta-amyloid, and Alzheimer's disease: tapping a sensitive connection. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  K. Beyreuther,et al.  Alzheimer's disease: modulation of the APP/A beta pathways towards rational therapeutic intervention , 2003 .

[22]  D. Schenk.  Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. , 2002, Nature reviews. Neuroscience.

[23]  M. Hennerici,et al.  Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  H. Cai,et al.  BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. , 2001, Nature neuroscience.

[25]  E. Kojro,et al.  Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. , 2001, Proceedings of the National Academy of Sciences of the United States of America.